CD7 is an inclusion criterion in 3 clinical trials for anaplastic large cell lymphoma, of which 3 are open and 0 are closed. Of the trials that contain CD7 status and anaplastic large cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 2 are phase 1 (2 open) [4].

CD7 is an inclusion criterion in 3 clinical trials for nasal type extranodal NK/T-cell lymphoma, of which 3 are open and 0 are closed. Of the trials that contain CD7 status and nasal type extranodal NK/T-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 2 are phase 1 (2 open) [4].

CD7 is an inclusion criterion in 3 clinical trials for T-cell acute lymphoblastic leukemia, of which 2 are open and 1 is closed. Of the trials that contain CD7 status and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is early phase 1 (1 open) and 2 are phase 1 (1 open) [4].

CD7 is an inclusion criterion in 2 clinical trials for adult T-cell leukemia/lymphoma, of which 2 are open and 0 are closed. Of the trials that contain CD7 status and adult T-cell leukemia/lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 1 is phase 1 (1 open) [4].

CD7 is an inclusion criterion in 2 clinical trials for angioimmunoblastic T-cell lymphoma, of which 2 are open and 0 are closed. Of the trials that contain CD7 status and angioimmunoblastic T-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 1 is phase 1 (1 open) [4].

CD7 is an inclusion criterion in 2 clinical trials for enteropathy-associated T-cell lymphoma, of which 2 are open and 0 are closed. Of the trials that contain CD7 status and enteropathy-associated T-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 1 is phase 2 (1 open) [4].

CD7 is an inclusion criterion in 2 clinical trials for peripheral T-cell lymphoma, not otherwise specified, of which 2 are open and 0 are closed. Of the trials that contain CD7 status and peripheral T-cell lymphoma, not otherwise specified as inclusion criteria, 1 is early phase 1 (1 open) and 1 is phase 1 (1 open) [4].

CD7 is an inclusion criterion in 2 clinical trials for T-cell lymphoblastic leukemia/lymphoma, of which 2 are open and 0 are closed. Of the trials that contain CD7 status and T-cell lymphoblastic leukemia/lymphoma as inclusion criteria, 2 are phase 1 (2 open) [4].

CD7 is an inclusion criterion in 2 clinical trials for T-cell non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain CD7 status and T-cell non-hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 1 is phase 1 (1 open) [4].

CD7 is an inclusion criterion in 2 clinical trials for T-cell prolymphocytic leukemia, of which 2 are open and 0 are closed. Of the trials that contain CD7 status and T-cell prolymphocytic leukemia as inclusion criteria, 1 is early phase 1 (1 open) and 1 is phase 1 (1 open) [4].

CD7 is an inclusion criterion in 1 clinical trial for anaplastic large cell lymphoma, ALK-negative, of which 1 is open and 0 are closed. Of the trial that contains CD7 status and anaplastic large cell lymphoma, ALK-negative as inclusion criteria, 1 is phase 1 (1 open) [4].

CD7 is an inclusion criterion in 1 clinical trial for lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CD7 status and lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

CD7 is an inclusion criterion in 1 clinical trial for monomorphic epitheliotropic intestinal T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CD7 status and monomorphic epitheliotropic intestinal T-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) [4].

CD7 is an inclusion criterion in 1 clinical trial for small intestinal lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CD7 status and small intestinal lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

CD7 is an inclusion criterion in 1 clinical trial for T-cell lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CD7 status and T-cell lymphoblastic lymphoma as inclusion criteria, 1 is early phase 1 (1 open) [4].